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inflammatory hyperalgesia
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Abstract
Glycinergic neurons and glycine receptors (GlyRs) exert a critical control over spinal nociception. Prostaglandin E2 (PGE2), a key
inflammatory mediator produced in the spinal cord in response to peripheral inflammation, inhibits a certain subtype of GlyRs
(a3GlyR) that is defined by the inclusion of a3 subunits and distinctly expressed in the lamina II of the spinal dorsal horn, ie, at the site
where most nociceptive nerve fibers terminate. Previous work has shown that the hyperalgesic effect of spinal PGE2 is lost in mice
lacking a3GlyRs and suggested that this phenotype results from the prevention of PGE2-evoked protein kinase A (PKA)-dependent
phosphorylation and inhibition of a3GlyRs. However, direct proof for a contribution of this phosphorylation event to inflammatory
hyperalgesia was still lacking. To address this knowledge gap, a phospho-deficient mouse line was generated that carries a serine to
alanine point mutation at a strong consensus site for PKA-dependent phosphorylation in the long intracellular loop of the GlyR a3
subunit. Thesemice showed unaltered spinal expression of GlyRa3 subunits. In behavioral experiments, they showed no alterations
in baseline nociception, but were protected from the hyperalgesic effects of intrathecally injected PGE2 and exhibited markedly
reduced inflammatory hyperalgesia. These behavioral phenotypes closely recapitulate those found previously in GlyR a3-deficient
mice. Our results thus firmly establish the crucial role of PKA-dependent phosphorylation of a3GlyRs in inflammatory hyperalgesia.
Keywords: Prostaglandin, Inflammation, Central sensitization, Phosphorylation, Knock-in, Dis-inhibition, Dorsal horn, Spinal
cord, Pain, Mouse, von Frey, Hargreaves test, Heat hyperalgesia, Allodynia
1. Introduction
Chronic pain is a growing concern worldwide, affecting roughly
20% of the population.26 It is a complex disorder associated with
alterations in the peripheral nervous system and central nervous
system. In most patients, chronic pain is maintained either by
inflammatory processes (inflammatory pain) or results from
damage to the somatosensory nervous system (neuropathic
pain). In both conditions, compromised functioning of inhibitory
circuits of the spinal cord crucially contributes to the development
and maintenance of chronic pain.3,36,41 At this site, inhibitory
neurotransmission is mediated by both glycine and g-aminobutyric
acid (GABA).30 Several reports from different groups have provided
compelling evidence for a critical role of glycinergic neurons and
glycinergic neurotransmission in the spinal control of nociception.
Blockade of spinal GlyRs with strychinine induces hyperalgesia,
allodynia and signs of spontaneous discomfort at subconvulsive
doses.6 Local ablation or silencing of dorsal horn glycinergic neurons
results in mechanical, heat, and cold hypersensitivity,11 and patients
with hyperekplexia who carry disease-causing mutations in glycine
receptors or glycine transporters also exhibit heightened pain
sensitivity.33 Moreover, recently developed positive allosteric GlyR
modulators and glycine transport inhibitors reduce hyperalgesia in
mouse models of chronic inflammatory and neuropathic pain.
1,16,24,38,39 For a recent review, see Ref. 40.
Although both inflammation and neuropathy compromise neuronal
inhibition in the spinal cord, underlyingmechanisms are rather different.
Peripheral nerve damage has been shown to lead to a microglia-
dependent disruption of the transmembrane chloride gradient that
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compromisesbothGABAergic andglycinergic inhibition,9,10while other
work has demonstrated that changes that specifically interfere with the
responsiveness of superficial dorsal horn glycinergic neurons and
glycine receptors (GlyRs) aremajor contributors to chronic inflammatory
pain. The spinal dorsal horn harbors an otherwise sparsely expressed
glycine receptor subtype characterized by the inclusion of GlyR a3
subunits in thechannelcomplex.13Mice lacking theseGlyRa3subunits
(gene nameGlra3) show normal baseline nociception, but are resistant
to the hyperalgesic effect of intrathecally injected PGE2 and show
markedly reduced hyperalgesia evoked by peripheral inflammatory
insults.13,27 Whole-cell recording experiments in superficial dorsal horn
neurons have shown that PGE2 inhibits glycinergic postsynaptic
currents in a protein kinase A (PKA)-dependentmanner, and additional
electrophysiological experiments on recombinant glycine receptors
expressed in HEK293T cells indicate that PKA phosphorylates a serine
residue (S346) in the long intracellular loopofGlyRa3subunitsbetween
transmembrane segments 3 and 4.1,13
Although these in vitro experiments suggested a critical role of
phosphorylation of GlyR a3 subunits at S346 in inflammation-
induced hyperalgesia, its relevance for in vivo inflammatory
hyperalgesia has not yet been directly demonstrated. Here, we
report the generation, and electrophysiological and behavioral
analysis of a GlyR a3 phospho-deficient (S346A point-mutated)
mouse line. The behavioral phenotypes observed in these mice
resemble those previously described for the GlyR a3-deficient
mice and firmly establish the critical role of PKA-dependent
phosphorylation and inhibition of a3GlyR in inflammatory
hyperalgesia.
2. Methods
2.1. Mouse breeding and maintenance
Experiments were performed in wild-type mice (C57BL/6),
GlyRa3(S346A) point-mutated mice (Glra3Tm1(S346A.Amg)), GlyR
a3 subunit-deficient mice (Glra3tm1.1Umu),13 and vGAT::ChR2
(Tg(Slc32a1-COP4*H134R/EYFP)8Gfng/J) BAC transgenic mice.42 All
mice were maintained on C57BL/6 genetic background. For
experiments involving optogenetic stimulation, the vGAT::ChR2
transgene was crossed into wild-type and GlyRa3 (S346A) point-
mutated mice. Mice were kept group-housed under intermediate
barrier conditions and under a 12/12-hour light/dark cycle with ad
libitum access to food and water. Permissions for all animal
experiments reported here were obtained from the Canton of
Zurich (licenses ZH011/2019, ZH031/2016, and ZH231/2017).
All animal experiments were conducted in compliance with the
relevant ethical regulations. Genotyping of GlyRa3(S346A) point-
mutated mice was performed with two separate PCR reactions
involving primers (1) and (2) for the wild-type allele and primers (1)




2.2. Electrophysiological recordings in spinal cord slices
Transverse lumbar spinal cord slices were prepared from 3 to 5
week-old vGAT::ChR2 BAC transgenic mice and from vGAT::
ChR2;GlyRa3(S346A) double transgenic mice of both sexes (for
details, see Ref. 1). In brief, 400 mm-thick transverse slices were
prepared from the lumbar spinal cord. Immediately after cutting,
slices were transferred to oxygenated (95% O2/5% CO2) artificial
cerebrospinal fluid (ACSF) containing (in mM): 120 NaCl, 5
HEPES, 26 NaHCO3, 1.25 NaH2PO4, 2.5 KCl, 2 CaCl2, 1 MgCl2,
and 10 glucose (pH 7.35) at 35˚C and incubated for at least for 1
hour before recording. Slices were then transferred to the
recording chamber, which was continuously perfused with
oxygenated ACSF at a flow rate of 1.5 to 2.0 mL/min.
Superficial dorsal horn neurons were visually identified using
infrared gradient contrast equipment. Recordings were made from
presumed excitatory interneurons located in lamina II identified by the
absence of a blue light–induced photocurrent. Whole-cell patch-
clamp recordings were made at room temperature at a holding
potential of260mVusingaHEKAEPC-10amplifier andPatchMaster
v2.11 software (HEKA Elektronik, Ludwigshafen/Rhein, Germany).
Patch pipettes (3.5 to 4.5 MV resistance) were prepared from
borosilicate glass capillaries and filled with internal solution containing
(in mM): 120 CsCl, 10 EGTA, 4 MgCl2, 0.5 GTP, 2 ATP, and 10
HEPES (pH7.30, adjustedwithCsOH).QX-314 (5mM)was added to
the internal solution to block voltage-activated Na1 currents of the
recorded cell. Light-evoked inhibitory postsynaptic currents (IPSCs)
were induced by whole-field blue light (473 nm) illumination of the left
or right dorsal horn with a Polychrome V monochromator (473 nm, 4
ms, 2.7 mW, Thermo Fisher Scientific, Waltham, MA).
Glycinergic light-evoked IPSCs were isolated using bicuculline
(10 mM (2)-bicuculline methochloride, Tocris, Bristol, United
Kingdom). After 5 min of baseline recording, slices were super-
fused with ACSF containing 1 mM PGE2 (Tocris) for 5 to 10
minutes. At the end of each recording, strychnine (0.5 mM) was
added to confirm the glycinergic nature of the recorded IPSCs.
Access resistancewas continuouslymonitored. Recordingswere
discarded if the access resistance changed by more than 25%.
The decay of IPSCs was fitted to a dual-exponential function
using IgorPro software (Wavemetrics Inc., Oregon).
2.3. Behavioral analyses
All behavioral experiments were conducted in 7 to 12 week-old sex-
matched mice by the same female experimenter blinded to the
genotypes or treatments of the mice. Mice were assigned to
treatment groups in a randomized manner. All behavioral experi-
ments were performed during light phase (10 AM - 3 PM; ZT03-08).
The effect of the S346A phospho-mutation on acute nociception
and on spinal PGE2-induced or peripheral zymosan A-induced
hyperalgesia was studied in 7 to 12 week-old sex-matched mice.
Spinal PGE2-induced hyperalgesia was studied in mice injected
intrathecally with PGE2 (0.4 nmoles/mouse in 5 mL ACSF, from
10 mM stock dissolved in ethanol) through the L5/L6 intervertebral
spaceunder brief (2 - 3min) anesthesiawith 2% isofluraneusinga10
mL Hamilton syringe and a 30-gauge needle. Inflammatory hyper-
algesia was evoked with zymosan A (0.06 mg in 20 mL saline)
subcutaneously injected into the plantar side of the left hind paw.
To study the effects of the phospho-mutation on neuropathic
pain,micewere subjected to a chronic constriction injury (CCI) of the
left sciatic nerve. In brief, 3 loose (5-0 surgical silk) ligatures were put
around the left sciatic nerve proximal to the trifurcation. None of the
mice showed signs of paralysis. Mechanical withdrawal threshold
and thermal withdrawal latency were assessed using electronic von
Frey filaments (IITC, Woodland Hills, CA) and a Hargreaves test
apparatus (IITC, Woodland Hills, CA), respectively.
To assessmotor coordination, animalswere placed onto a rotarod
setup (IITC,WoodlandHills, CA). The rodwas set to accelerate from4
to 40 rpm over a period of 300 s. Two training sessions on the same
accelerating rod were performed 3 days before the actual test. In the
test session, the latency to fall from the rodwas recorded 5 times per
mouse with 10-min intervals between tests, during which the mouse
was placedback into its homecage. Averages of the 5 test runswere
calculated for each mouse.
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2.4. Immunohistochemistry
Threemicepergenotypewereanaesthetizedwithsodiumpentobarbital
and intracardially perfused with ice-cold ACSF at room temperature
for 2 min (2 mM CaCl2, 2 mM MgCl2, 30 mM glucose, 5 mM KCl,
119 mM NaCl, 25 mM HEPES, pH 7.4). The lumbar spinal cord
was rapidly dissected, frozen on powdered dry ice, and stored at
280˚ until used. Approximately 20 mm-thick cryostat-cut sections
mounted onSuperFrost Plus glass slides (Thermo Fisher Scientific,
Reinach, Switzerland) were fixed with 4% PFA in PBS for 2.5
minutes at room temperature. For antigen retrieval, the sections
were incubated in 10mMcitrate buffer pH6.0, 0.05%Tween20 for
30 min at 90˚C. After cooling to room temperature, the sections
were washed in PBS and incubated in blocking/permeabilization
solution (TBS containing 10% normal goat serum and 0.5% Triton
X-100) for 30 min. Subsequently, the solution was removed, and
the sections were incubated overnight at 4˚C with a rabbit
polyclonal antiserum directed against the GlyR a3 subunit13
diluted 1:100 in TBS containing 10% NGS and 0.5% Triton X-
100. After extensive washing (5 times for 5 min in TBS, 0.05%
Tween 20), the sections were incubated with fluorophore-labeled
secondary antibody (donkey anti-rabbit Alexa Fluor Plus 488,
Thermo Fisher Scientific, Reinach, Switzerland) diluted 1:2000 in
TBS containing 10% NGS and 0.05/Tween 20 for 1 hour at room
temperature. The sections were then extensively washed and
coverslipped in DAKO Fluorescence Mounting Medium. Images of
the labeled sections were acquired using a Zeiss LSM 800
microscope equipped with a 25x objective.
GlyR a3 immunofluorescence intensity was quantified using the
Image J software (https://imagej.nih.gov/ij). Raw fluorescence in-
tensity values were determined by dividing the sum of fluorescence
gray values in each pixel of laminae I and II of the dorsal horn gray
matter by the number of the analyzed pixels. Nonspecific fluores-
cence, measured ventral of the immunopositive lamina II, was
subtracted to obtain the GlyR a3 immunofluorescence. The same
regions were analyzed in all sections.
2.5. Statistics
Statistical analyses of electrophysiological data were performed
with 2-tailed unpaired t tests. Behavioral data were analyzed with
2-tailed unpaired t tests or with 2-way repeated measures
analysis of variance (ANOVA) followed by Bonferroni post hoc
tests. Quantifications of the morphological data were performed
with 1-way ANOVA with the Tukey multiple comparison test.
3. Results
3.1. Generation of S346A GlyR a3 phospho-deficient mice
and baseline morphological and
electrophysiological characterization
GlyRa3(S346A) point-mutated mice were generated using
CRISPR technology. The serine (S) residue 346, which
constitutes the phosphorylation site within a strong consensus
sequence for PKA-dependent phosphorylation (RESR) in the
long intracellular loop of the GlyR a3 subunit (Fig. 1A), was
mutated into an alanine (A) by changing the serine encoding
base triplet AGT to GCT (Fig. 1B). A mixture containing active
guide RNA molecules, a single stranded oligodeoxynucleotide
donor, and qualified Cas-9 mRNA was injected into the
cytoplasm of C57BL/6N embryos that were subsequently
implanted into pseudopregnant female mice. Genotyping of
pups was performed by genomic DNA sequencing (Fig. 1B) or
using a PCR with mutation-specific primers (Fig. 1C). No
differences in the levels of GlyR a3 subunit expression were
found in transverse sections of the lumbar spinal cord of wild-
type mice and homozygous a3 GlyR (S346A) point-mutated
mice (Fig. 1D). Specificity of the antibody was confirmed in
sections prepared from GlyR a3-deficient mice.
3.2. Electrophysiological characterization of inhibitory
synaptic transmission in the superficial spinal dorsal horn
We next performed a first electrophysiological characterization of
inhibitory synaptic transmission in the GlyRa3(S346A) point-mutated
mice and combined electrophysiological whole-cell patch-clamp
recordings in transverse lumbar spinal cord sliceswith anoptogenetic
approach to trigger synaptic neurotransmitter release from inhibitory
neurons (Fig. 2A). To this end, we used wild-type mice and
homozygous GlyRa3(S346A) point-mutated mice that carried the
vGAT::ChR2bacterial artificial chromosome transgene. In spinal cord
slices prepared from these mice, a 1-s blue light (473 nm) pulse
induced a depolarizing photocurrent in voltage-clamped inhibitory
neurons, while exposure to shorter (4ms) blue light pulses in current-
clamp evoked single action potentials in these neurons and triggered
IPSCs in synaptically connected cells.11 Targeted whole-cell
recordings were performed from photocurrent-negative (presumed
excitatory) neurons.1,31 Excitatory interneurons of the dorsal horn
havepreviously been shown to serve an important role in pathological
pain states.35Brief wide-field blue light exposure of slices of wild-type
andhomozygousGlyRa3(S346A) point-mutatedmiceevoked IPSCs
in all recorded neurons (n 5 28 and 22, for wild-type and GlyR
a3(S346A) point-mutated, respectively) (Figs. 2B–D). IPSC ampli-
tudes were measured, and their decay kinetics were determined by
calculating a weighted tw
19 from a double exponential fit of the falling
phase of the IPSC. Significant difference in the amplitudes of total
IPSCs and of their glycinergic components (gly-IPSC) were found
between wild-type and GlyRa3(S346A) point-mutated mice (Figs.
2B and D). Total IPSC amplitudes were25896 62 pA in wild-type
mice (n528) vs212286108pA in S346Apoint-mutatedmice (n5
22) (P, 0.0001, unpaired t test). Average gly-IPSC amplitudes were
2288.5631.50 pA in wild-typemice (n5 15) vs2632.06155.7 in
S346A point-mutated mice (n5 13) (P5 0.029, unpaired t test). No
difference was observed in the decay time course of the total IPSCs
and the gly-IPSCs between wild-type and GlyRa3(S346A) point-
mutatedmice. Average decay time constants of the total IPSC 161.5
6 30.7 ms for wild-type mice (n5 28) vs 119.16 34.1 ms in S346A
point-mutated mice (n 5 22) (P 5 0.36, unpaired t test). Average
decay time constants of the gly-IPSC were 68.7 6 12.8 ms in wild-
typemice (n5 15) vs 55.068.2ms in S346A point-mutatedmice (n
5 13) (P5 0.39, unpaired t test) (Fig. 2D).
3.3. Effects of prostaglandin E2 on glycinergic synaptic
transmission in the superficial spinal dorsal horn
Previous work has shown that PGE2 reduces the amplitudes of
gly-IPSCs in superficial dorsal horn neurons of wild-type
mice1,13,27,29 and that GlyR a3-deficient mice were protected
from this inhibitory effect.1,13,27 We therefore examined the
effects of PGE2 on gly-IPSCs that were recorded from
superficial dorsal horn neurons of homozygous GlyRa3(S346A)
point-mutated mice and isolated with bicuculline (10 mM). We
found that amplitudes of gly-IPSCs in GlyRa3(S346A) point-
mutated mice were unaffected by PGE2 (1 mM), while gly-IPSCs
in neurons of mice carrying wild-type a3 GlyR showed the
expected inhibition (Figs. 3A and B). PGE2 reduced amplitudes
of gly-IPSCs in wild-type mice (n5 15) from2288.5 6 31.5 pA
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to 2122.4 6 15.7 pA (on average by 54 6 7%) (P , 0.001,
paired t test). In S346A point-mutatedmice (n5 13), amplitudes
decreased from 2632.0 6 155.7 pA to 517.3 6 123.3 pA (on
average by 96 11%),P5 0.065, paired t test) (Fig. 3C). Percent
inhibition by PGE2 in wild-type mice was significantly different
from inhibition in S346A point-mutated mice (P 5 0.0012,
unpaired t test). No changes in decay kinetics by PGE2 were
observed in either genotype. In wild-type mice (n 5 15), tw
decreased from 68.76 12.8 ms to 48.56 14.2 ms (on average
to 78.0 6 19.3%) during PGE2 application (P 5 0.15, paired t
test). In S346A point-mutated mice (n 5 13), it changed from
55.06 8.2ms to 44.76 9.5ms (on average to 89.66 19.5%) (P
5 0.32, paired t test). No significant difference in the percent
change of tw between wild-type and S346A point-mutatedmice
was found (P 5 0.68, unpaired t test) (Fig. 3D).
3.4. Baseline nociceptive sensitivities of GlyRa3(S346A)
point-mutated mice
As the next step, we compared the somatosensory and
nociceptive sensitivity of naive wild-type and homozygous
GlyRa3(S346A) point-mutated mice (Fig. 4). No significant
difference in response latencies were found between these
mouse lines upon exposure to noxious heat (wild-type (n 5 10):
20.06 1.4 s vs S346A point-mutatedmice (n5 14): 21.36 0.9 s;
unpaired t test; P 5 0.47) and noxious cold (wild-type (n 5 10):
5.2 6 0.3 s vs S346A point-mutated mice (n 5 9): 5.4 6 0.3 s;
unpaired t test; P 5 0.72) (Figs. 4A and B). Similarly, no
differences were detected in response frequencies upon noxious
mechanical stimulation (pin-prick response score; Fig. 4C) (wild-
type (n 5 5): 0.8 6 0.06 vs S346A point-mutated mice (n 5 7):
0.81 6 0.05; P 5 0.91, unpaired t test), in response thresholds
upon exposure to punctuate mechanical stimuli applied with von
Frey filaments (Fig. 4D) (wild-type (n5 10): 4.26 0.2 g vs S346A
point-mutated mice (n 5 12): 4.2 6 0.1 g; P 5 0.87, unpaired t
test). Similarly, no differences were observed in response
frequencies (scores) upon brush stimulation (wild-type (n 5 7):
0.886 0.051vs S346A point-mutatedmice (n5 6) 0.926 0.053;
P5 0.64, unpaired t test) (Fig. 4E). In addition, no difference was
found in the rotarod performance between genotypes (wild-type
(n 5 5): 117.7 6 15.1 s vs S346A point-mutated mice (n 5 8):
92.0 6 10.8 s; P 5 0.19, unpaired t test) (Fig. 4F).
3.5. Lack of hyperalgesic effects of intrathecal prostaglandin
E2 in GlyRa3(S346A) point-mutated mice
Previous work has shown that GlyR a3-deficient mice were
protected from the behavioral pain sensitization elicited by
Figure 1. GlyRa3(S346A) point-mutated mice. (A) Schematic illustration of the murine Glra3 gene locus indicating the PKA consensus site in exon 7 (X7) and the
targeted codon of serine 346 (S*). (B) DNA sequencing: Pherograms of homozygous wild-type (wild-type/wild-type; top) and homozygous S346A/S346A-point-
mutated mice (bottom). Red rectangle indicates the mutated amino acid residue and DNA base triplet, black arrows point to the mutated DNA bases. Gray arrow
indicates a silent additional mutation of a single DNA base. (C) PCR genotyping: PCR products obtained from genomic DNA samples from homozygous wild-type
(wild-type/wild-type), heterozygous (wild-type/S346A), and homozygous S346A/S346A point-mutatedmicewith primer pairs specific for thewild-type andS346A
point-mutated allele. (D) GlyR a3 subunit expression in wild-type, homozygous S346A point-mutated mice and GlyRa3-deficient mice. Example confocal images
of transverse lumbar dorsal horn sections immunostained for GlyR a3 subunits, scale bar 20 mm. Quantification of the fluorescence intensity in 10 sections per
genotype from 3 animals (1-way ANOVA followed by Tukey multiple comparison test; data are expressed as mean 6 SD). **** P,0.0001. ANOVA, analysis of
variance.
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Figure 2. Inhibitory synaptic transmission in GlyRa3(S346A) point-mutated mice. (A) Experimental set-up for combined electrophysiological optogenetic
experiments. (B) Left: Average traces of total (mixed GABAergic/glycinergic) IPSCs recorded from wild-type and homozygous GlyRa3(S346A) point-mutated
mice. Blue lines indicate time points of optogenetic blue light stimulation. Right: statistical comparison. Scattered plot, data points represent 28 and 22 individual
neurons from21wild-type and 15 homozygous S346A/S346A point-mutatedmice, respectively. Lines indicatemean6SEM.P, 0.01, unpaired two-sided t test.
(C) Same as (B) but decay kinetics of total IPSCs. Left: scaled average traces (black) with double exponential fits superimposed (red). Quantification of decay
kinetics in wild-type and GlyRa3(S346A) point-mutated mice. (D) Analysis of amplitudes and decay kinetics of the glycinergic IPSC component isolated with
bicuculline (10 mM). Fifteen and 13 neurons from 13 wild-type and 9 homozygous S346A/S346A point-mutated mice, respectively. Quantification of glycinergic
decay kinetics in wild-type and GlyRa3(S346A) mice. IPSC, inhibitory postsynaptic current.
2440 K. Werynska et al.·162 (2021) 2436–2445 PAIN®
spinal PGE2.
13,27 We repeated these experiments in
GlyRa3(S346A) point-mutated mice and injected PGE2 (0.4
nmoles in 5 mL ACSF) intrathecally (ie, into the subarachnoid
space) at the level of the lumbar spinal cord. As expected,
in wild-type mice, PGE2 induced a transient mechanical
hyperalgesia lasting for several hours. No such hyperalgesia
was observed in GlyRa3(S346A) point-mutated mice (Figs. 5A
and B). Two-way repeated measures ANOVA revealed signif-
icant time * genotype interactions for both sensory tests
(Hargreaves: F(5,80) 5 31.41, P , 0.0001; von Frey: F(5,80)
5 13.05, P , 0.0001). Bonferroni post hoc tests identified
significant differences between the 2 genotypes at 30, 60, 90,
and 120 min after PGE2 injection (P, 0.001 for 30, 60, 90, and
120 min for both Hargreaves and von Frey tests). No statistically
significant heat sensitization was detected in homozygous
GlyRa3(S346A) point-mutated mice (1-way repeated measures
ANOVA; F(5,40) 5 1.30; the Dunnett multiple comparison test
P $ 0.3 for all time points). Similarly, no statistically significant
mechanical sensitization was detected in homozygous
GlyRa3(S346A) point-mutated mice (1-way repeated measures
ANOVA; F(5,40)5 2.38; the Dunnett multiple comparison test P
$ 0.06 for all time points).
3.6. Reduced inflammatory hyperalgesia but retained
neuropathic sensitization after peripheral nerve injury
We next used the zymosan Amodel to induce peripheral inflammation
in the left hind paw. Previous work has shown that in this model, heat
hyperalgesia and mechanical hyperalgesia depend on spinal PGE2
formation and that GlyR a3-deficient mice exhibit less hyperalgesia in
this model than wild-type mice.27 We therefore tested GlyRa3(S346A)
point-mutated also in the zymosan A model and injected zymosan A
Figure 3. Lack of inhibition of gly-IPSCs by PGE2. (A) Average traces of 10 consecutive light-evoked gly-IPSCs in wild-type (wild-type) and S346A point-mutated
mice (S346A) before (black) and after (red) PGE2 (1 mM) application. (B) Time course of gly-IPSC amplitudes (mean6 SEM) before and during application of 1 mM
PGE2. (C) Statistical analyses of gly-IPSC amplitude changes. Data points represent individual neurons. Left andmiddle panel: PGE2 effect in wild-type and S346A
point-mutated mice, respectively (wild-type: n5 15 cells from 13mice; S346A: n5 13 cells from 9 mice). Paired two-sided t tests. Right: comparison of gly-IPSC
by PGE2 in wild-type (wild-type) and S346A point-mutated mice (S346A) mice. (D) Same as (C) but weighted decay time constants. IPSC, inhibitory postsynaptic
currents; PGE2, prostaglandin E2.
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(0.06mg in 20mL saline) subcutaneously into the left hindpaw.Relative
to their wild-type littermates, GlyRa3(S346A) point-mutated developed
significantly less inflammatory hyperalgesia. In case of the Hargreaves
test, 2-way repeated measures ANOVA revealed a significant time *
genotype interaction (F(6,84)5 5.93;P, 0.0001; n5 9 and 7 forwild-
type and S346 point-mutated mice mice). Significant differences
between genotypes were found for day 1 (P , 0.0001), day 2 (P ,
0.01), day 3 (P,0.001), andday4 (P,0.01)) (Fig. 5C). A similar time *
genotype interaction was also found for the von Frey test ((F(6,84) 5
7.27;P, 0.0001; n5 9 and 7 for wild-type andS346Apoint-mutated
mice). In this test, significant differencesbetweengenotypeswere again
found for day 1 (P, 0.0001), day 2 (P, 0.0001), day 3 (P, 0.0001),
and day 4 (P , 0.01)) (Fig. 5D). We used 1-way repeated measures
ANOVA to test whether in GlyRa3(S346A) point-mutated mice
developed significant heat or mechanical hyperalgesia. No such heat
sensitizationwasdetected ineither theHargreaves test (1-way repeated
measuresANOVA; F(6,36)52.6, theDunnettmultiple comparison test
P $ 0.14 for all time points) or the von Frey test (F(6,36) 5 3.53, the
Dunnett multiple comparison test P$ 0.08 for all time points).
We also tested whether wild-type mice and GlyRa3(S346A)
point-mutated mice would differ in their mechanical or thermal
hypersensitivity developed in response to a peripheral nerve injury
induced by a chronic constriction injury of the sciatic nerve. In
these experiments, we found indistinguishable heat and me-
chanical hyperalgesia 7 days after chronic ligation of the sciatic
nerve (Figs. 5E and F) (Hargreaves: wild-type (n 5 9): 5.48 6
0.41 s; S346A (n 5 7): 4.35 6 0.39 s; P 5 0.07, unpaired t test.
von Frey: wild-type (n5 8): 1.336 0.06 g; S346A (n5 7): 1.416
0.09 g; P5 0.46, unpaired t test), again consistent with previous
reports showing that a3GlyRs are is not directly involved in the
neuropathic pain development or maintenance.14,15
4. Discussion
In this study, we have used morphological, electrophysiological,
and behavioral methods to assess the contribution of the S346
phosphorylation site of the GlyR a3 subunit to the inhibition of
glycinergic neurotransmission by PGE2 and to inflammatory or
neuropathic hyperalgesia. The results of the electrophysiological
experiments indicate that the introduction of the phospho-
deficient S346A point mutation into the GlyR a3 subunit of mice
rendered dorsal horn glycine receptors insensitive to the inhibitory
action of PGE2. Behavioral experiments demonstrate that naive
GlyRa3(S346A) point-mutated mice exhibit unaltered nocicep-
tive, somatosensory, and gross motor functions. However, unlike
wild-type mice, GlyRa3(S346A) a3GlyRs are mice failed to
develop nociceptive sensitization after intrathecal PGE2 injection.
These mice also showed less sensitization than wild-type mice in
the zymosan A model of inflammatory hyperalgesia. Thus,
GlyRa3(S346A) point mutated mice closely recapitulate the
phenotypes previously described for GlyR a3-deficient mice.13,27
Importantly, unaltered GlyR a3 immunoreactivity in wild-type and
GlyRa3(S346A) point-mutated mice ruled out that the similarity of
the phenotypes was caused by reduced expression of point-
mutated GlyR a3 subunits. The results presented here hence
provide compelling support for a major contribution of PKA-
Figure 4.Gross characterization of baseline nociceptive sensitivity in naive wild-type and GlyRa3(S346A) point-mutated mice. (A) Hargreaves test (n5 10 and 14
for wild-type and S346Amice, respectively), (B) cold plantar test (n5 10 and 9 for wild-type and S346A mice, respectively), (C) pin-prick test (n5 5 and 7 of wild-
type and S346A mice, respectively), (D) von Frey test (n 5 10 and 12 for wild-type and S346A mice, respectively), (E) brush test (n 5 7 and 9 for wild-type and
S346A mice, respectively), and (F) rotarod (n5 5 and 8 for wild-type and S346A mice, respectively). Data points are individual mice. Lines indicate mean6 SEM.
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dependent phosphorylation and inhibition of a3GlyRs to centrally
mediated inflammatory hyperalgesia.
The rate-limiting step in the formation of prostaglandins is the
activity of prostaglandin H synthase, better known as cyclo-
oxygenase (COX), which exist in 2 isoforms (COX-1 and COX-2).
Prostaglandin formation in the CNS depends mainly on COX-2
whose spinal expression increases after peripheral inflamma-
tion.4,27,28 The rise in spinal PGE2 that occurs after peripheral
insults depends mainly, if not exclusively, on the induction of
COX-2 expression. Our results therefore allow insights into the
role of spinal COX-2 and PGE2 in hyperalgesia of different
etiologies. Although a contribution of COX-2 and PGE2 to
inflammatory hyperalgesia is universally accepted, their role in
neuropathic hyperalgesia is less clear. Some evidence suggests a
role of COX-2 and PGE2 through macrophages infiltrating the
peripheral injured nerve,20,21 but a contribution of spinal COX-1 or
COX-2 has also been proposed.7,22
In a previous report,15 we have addressed the susceptibility to
neuropathic hyperalgesia in GlyR a3-deficient mice. This study
analyzed neuropathic sensitization at short intervals over a 20-day
period after chronic constriction injury (CCI) surgery and found no
differences in sensitization between wild-type mice and GlyR a3-
deficient mice at any time point. In this study, normal development
of neuropathic sensitization was observed in addition in the
GlyRa3(S346A) point-mutated mice. Both studies indicate that
COX-2/PGE2-evoked PKA-dependent phosphorylation of
a3GlyRs is dispensable for the development of neuropathic
hyperalgesia after peripheral nerve injury. This result is consistent
with several previous reports that found only a minor induction of
spinal COX-2 in the spared nerve injury model8 and no
antihyperalgesic effect of the selective COX-2 inhibitors celecoxib
and rofecoxib in rats with a spared nerve or chronic constriction
injury of the sciatic nerve.7,8 It should however be noted that COX-2
may have functions different from prostaglandin production, eg, in
the metabolism of endocannabinoids18; hence, antihyperalgesic
effects of COX-2 inhibitors that are unrelated to the block of
prostaglandin formation cannot be excluded based on the present
results.29
The unaltered development of neuropathic hyperalgesia in
GlyR a3-deficient and GlyRa3(S346A) point-mutated mice does
not exclude that a3GlyRs still control neuropathic hyperalgesia.
Neurons expressing a3GlyRs may still very well be parts of
circuits controlling neuropathic pain. Previous reports have in fact
demonstrated that superficial dorsal horn excitatory interneurons
Figure 5. Inflammatory and neuropathic pain sensitization inwild-type andGlyRa3(S346A) point-mutatedmice. (A andB) Heat (A) andmechanical sensitization (B)
evoked by intrathecal PGE2 injection (0.04 nmoles per mouse). n 5 9, for both genotypes and tests. The latency (Hargreaves test) and threshold (von Frey test)
difference between the test groups were significant at 30 min, 60 min, 90 min, and 120 min after PGE2 injection (2-way repeated measures ANOVA with the
Bonferroni post hoc test). Data are expressed asmean6SEM. ***P, 0.001. (C andD) Same as (A andB) but inflammatory hyperalgesia evoked by subcutaneous
injection of zymosan A into the left hind paw. n5 7 and 9 mice for wild-type and GlyRa3(S346A) point-mutated mice, respectively). Two-way repeated measures
ANOVA followed byBonferroni post hoc tests revealed significant between the genotypes difference at days 1 to 4. ***P, 0.001; **P, 0.01. (E and F) Neuropathic
sensitization induced by chronic constriction injury surgery of the left sciatic nerve. n 5 7 and 9 mice for wild-type and GlyRa3(S346A) point-mutated mice. No
significant difference were found between genotypes (2-way repeatedmeasures ANOVA, F(1,14)5 0.28;P5 0.61.P values shown in the figure are from unpaired
t tests. ANOVA, analysis of variance; PGE2, prostaglandin E2.
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are part of a circuit that is required for complex behaviors in
neuropathic pain states.35 Although the electrophysiological
recordings in 2 of our previous studies2,13 were made from
unidentified lamina II neurons, in this study, targeted recordings
weremade from identified excitatory neurons in lamina II. The new
results indicate that PGE2-mediated inhibition of glycinergic
neurotransmission occurs in excitatory interneurons. Efficacy of
GlyR modulators in rodent neuropathic pain models is supported
by a study that tested a recently developed positive allosteric
modulator of glycine receptors (AM-1488)16 and a second study
that investigated dehydroxyl-cannabidiol (DH-CBD), a cannabi-
noid derivative with no activity at classical cannabinoid CB1 and
CB2 receptors but potentiating actions at GlyR a3 receptors.39
It is tempting to speculate about implications of our findings for
pain therapy and pain genetics in humans. The phenotype of the
GlyRa3(S346A) point-mutated mice in models of inflammatory pain
may suggest that COX inhibitors that reach COX-inhibiting
concentrations in the CNS should be superior to drugs that do not
penetrate the blood-brain barrier. This concept remains to be
thoroughly tested in humans.34 On the other hand, the lack of a
phenotype in GlyRa3(S346A) point-mutated and GlyRa3-deficient
mice correspondswell with the low efficacy ofCOX inhibitors against
neuropathic pain in patients.
Given that human genetic mutations can cause pronounced
changes in pain sensitivity,5 we also felt tempted to investigate
whether genetic variants exist in the humanGLRA3 gene potentially
recapitulating the effects of the murine Glra3 gene deletion or the
S346A point mutation. The human GLRA3 (UniprotKB-entry
075311) and the corresponding murine Glra3 (UniprotKB-entry
Q91XP5) share 98.9% of their amino acids (459 of the 464). In the
large intracellular loop spanning positions 336 to 430, the homology
is 95.8% with a complete conservation of the phosphoserine sites,
suggesting that at a structural and functional level, the roles of these
channel ismost likely conserved across the 2 species.We therefore
searched the NCBI variation database (www.ncbi.nlm.nih.gov/
variation/) for nonsensemutations causing apremature translational
stop, for small insertion/deletion mutations that cause a shift in the
reading frame, and for missensemutations in the RESR consensus
site for PKA dependent phosphorylation. We found 3 missense
mutations in the RESR motive (rs1179069123: S → N amino acid
exchange, rs 1561028476: S→R, and rs145802010: R→Q in the
fourth position of the RESR consensus motive). All 3 variants are
extremely rarewithminor allele frequencies of 831026 to 231024
(www.ncbi.nlm.nih.gov/snp/). Even in the case of themost frequent
variant (rs145802010), the whole human population very likely
includes less than 200 persons homozygous for the R → Q
mutation. Fourteen nonsense mutations (premature stop codons)
and 8 frame-shift mutations were identified, of which all but 1
occurred with minor allele frequencies, 13 1025. One frame-shift
mutation (rs200339054) has aminor allele frequency of 1.63 1024,
suggesting a frequency of homozygous carriers of 2.4 3 1028
(equivalent to 25 homozygous carriers per 1 billion persons). Hence,
mutations in the humanGLRA3 gene occur with frequencies far too
low for systematic analyses in clinical studies. Furthermore, given
the generally mild phenotypes observed in heterozygous carriers of
loss-of-function alleles, most de novo mutations in GLRA3 should
not leads to apparent symptoms in humans.
An unexpected finding in the electrophysiological experiments
was a change in baseline inhibitory synaptic transmission, namely
an increase in gly-IPSC (and also total IPSC) amplitudes of
GlyRa3(S346A) point mutated mice. Such an increase was not
observed in previous experiments on GlyRa3-deficient mice. Part
of this increase might be explained by the slightly (about 10%)
higher open probability of S346A point-mutated a3GlyRs
observed in experiments on recombinant receptors.23 Block of
constitutive GlyR a3 phosphorylation at S346A and subsequent
prevention of inhibition of glycine receptors in the point-mutated
mice may also contribute. However, these 2 potential mecha-
nisms can still not fully explain the observed changes, as an
increase in the IPSC amplitude explains only half of the increase in
the total IPSC amplitude, suggesting that GABA-IPSCs were also
increased. At present, we can only speculate about the
underlying processes. Presynaptic mechanisms might be in-
volved. GlyRs have been found on presynaptic terminals of spinal
neurons where they modulate transmitter releases through the
activation of a depolarizing Cl2 current.32 Because GABA and
glycine are coreleased in the spinal cord from the same
presynaptic vesicles,17 enhanced presynaptic GlyR activity might
increase synaptic release of both glycine and GABA. Given the
supralinear dependence of transmitter release on presynaptic
depolarization and Ca21 influx, a relatively small increase in GlyR
activity in the S346A point-mutated mice, eg, by the mechanisms
discussed above, may trigger disproportional larger increase in
IPSC amplitudes. However, postsynaptic mechanisms are also
possible. Phosphorylation of glycine and GABAA receptors has
been shown to impact their lateral diffusion into and out of
postsynaptic receptor clusters by changing their interaction with
the postsynaptic scaffolding protein gephyrin.25 In addition,
secondary activity-dependent changes in the gephyrin scaffold12
may alter GABAA receptor recruitment or residence time in the
GlyRa3(S346A) point-mutated mice.
In summary, our results provide direct evidence for a critical
contribution of GlyR a3 phosphorylation to inflammatory hyper-
algesia and further support a3GlyRs as targets for novel
analgesics.
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MOH, Zeilhofer HU, Fritschy JM, Tyagarajan SK. Several posttranslational
modifications act in concert to regulate gephyrin scaffolding and
GABAergic transmission. Nat Commun 2016;7:13365.
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